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Aims: To identify specific gut bacteria associated with coeliac disease (CD) at the diagnosis and 
after treatment with a gluten-free diet (GFD) in paediatric population. 
Methods: 30 and 18 faecal samples from untreated and treated CD patients and 25 and 8 biopsy 
samples from untreated and treated CD patients, respectively, were analyzed. In addition, 30 
faecal and 8 biopsy samples from control children were evaluated for comparative purposes. Gut 
bacterial groups were quantified by real-time PCR. 
Results: Bacteroides and C. leptum groups were more abundant in faeces and biopsies of CD 
patients than in controls regardless the stage of the disease. E. coli and Staphylococcus counts 
were also higher in faeces and biopsies of non-treated CD patients than in those of controls but 
their levels were normalized after treatment with a GFD. Bifidobacterium levels were lower in 
faeces of both CD patients as well as in biopsies of untreated CD patients compared to controls. 
Similar bacterial groups were related to CD in biopsies and faeces, indicating that faecal 
microbiota partly reflects that of the small intestine in CD patients, and could constitute a 
convenient biological index of this disorder.  
Conclusions: Duodenal and faecal microbiota is unbalanced in children with untreated CD and 
only partially restored after long-term treatment with a GFD, constituting a novel factor linked to 
this disorder.  
 
Abbreviations: CD, coeliac disease; GFD, gluten-free diet; IBD, IBD. 
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INTRODUCTION 
Coeliac disease (CD) is a chronic inflammatory disorder of the small intestine characterized by a 
permanent intolerance to dietary gluten. This disease can manifest at any age with a variety of 
clinical features, but typical cases often presents in early childhood. [1] In the patients, gluten 
peptides elicit a Th1-type inflammatory immune response that causes intestinal villous atrophy, 
crypt hyperplasia and infiltration of intraepithelial lymphocytes. The ingestion of gluten is 
responsible for the signs and symptoms of CD, and its removal from the diet is currently the only 
available treatment. Moreover, other factors such as imbalances in the intestinal microbiota have 
been suggested to be associated with this disorder. [2-4]   Infections could be involved in CD 
pathogenesis by both impairing mucosal barrier function and favouring the access of dietary 
gluten to sub-epithelial lymphoid tissue, and promoting a defensive Th1-mediated immune 
response with production of pro-inflammatory cytokines. [5] So far, differences in the microbiota 
composition and related metabolites between CD patients and healthy controls have been 
reported mainly in faeces, [3, 6, 7] whereas less information is available on the mucosa-
associated microbiota.[2, 4] A rod-shape bacterium was previously found in most biopsy 
specimens of adult CD patients but it was not identified. [2] More recently, specific studies have 
been carried out to characterize the duodenal microbiota of CD patients [4]; however, 
comparisons between mucosal and faecal microbiota in patients with active disease and treated 
with a gluten-free diet (GFD) are not available so as to define which are the bacterial groups 
relevant to the disease. In fact, other reports have described differences between the microbiota 
composition of mucosal and faecal samples in healthy subjects [8] as well as in allergy and 
inflammatory bowel disease (IBD) patients. [9, 10]  
The objective of this study was to assess in a comparative manner the composition of the 
duodenal and faecal microbiota of CD patients (untreated and treated with a GFD) and healthy 
age-matched controls, as well as to establish possible relations between biopsy and faecal 
associated bacteria and this disorder by the use of real-time PCR.  
 
PATIENTS and METHODS 
Subjects 
Three groups of children were included in this study: (1) untreated CD patients on a normal 
gluten-containing diet (56.4-60.6 months old); (2) treated CD patients with a GFD for at least 2 
years (63.5-57.8 months old); and (3) control children without gluten intolerance (45.0-49.2 
months old). The following faecal samples and duodenal biopsy specimens were analysed: 30 
faecal and 25 biopsy samples from untreated CD patients; 18 faecal and 8 biopsy samples from 
treated CD patients and 30 faecal and 8 biopsy samples from control children.  None of the 
children included in the study was treated with antibiotics for at least 1 month before the 
sampling time.  
 
Sample preparation and DNA extraction  
Faecal and biopsy samples were frozen immediately at -20ºC and kept until processing. Duodenal 
biopsy specimens were obtained by upper intestinal capsule or endoscopy. Faeces (1g) and 
duodenal biopsy samples (10-15 mg) were diluted 1: 10 (w/v) in PBS (pH 7.2), homogenized and 
used for DNA extraction. DNA from pure cultures of reference bacterial strains and faecal and 
biopsy samples were extracted using the QIAamp DNA stool Mini kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions. 
 
Quantitative real-time PCR (qPCR) analysis 
Quantitative real time PCR was used to characterize the gut microbiota by use of specific primers 
targeting different bacterial groups and the SYBR® Green PCR Master Mix (SuperArray 
Bioscience Corporation, USA), as previously described (Table 1). PCR amplification and 
detection were performed with an ABI PRISM 7000-PCR sequence detection system (Applied 
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Biosystems, UK). Bacterial concentration from each sample was calculated by comparing the Ct 
values obtained from standard curves that were created by using serial 10-fold dilution of pure 
cultures DNA corresponding to 102 to 109 cells. The following strains were used as references: 
Bifidobacterium longum subsp. longum CECT 4503, Bacteroides fragilis DSMZ 2451, 
Clostridium coccoides DSMZ 933, C. leptum DSMZ 935, Staphylococcus aureus CECT 86, 
Lactobacillus casei ATCC 393, E. coli CECT 45 and Akkermansia muciniphila strain MucT 
(ATCC BAA-835T).  
 
Statistical analyses  
Statistical analyses were done using the SPSS 11.0 software (SPSS Inc, Chicago, IL, USA). Due 
to non-normal distribution, microbial data are expressed as medians with interquartile ranges 
(IQR) and the differences between two groups of samples were determined by applying the 
Mann–Whitney U test. Correlations between variables were determined by applying the 
Spearman rank correlation coefficient. Differences in prevalence of bacterial groups were 
established by applying the chi-square test. A p < 0.050 was considered statistically significant. 
 
RESULTS 
Subjects 
Clinical characteristics of the different groups of CD children included in the study are shown in 
Table 2.  
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Untreated CD patients were on a normal gluten-containing diet, showed clinical symptoms of the 
disease, positive coeliac serology markers (anti-gliadin antibodies and anti-transglutaminase 
antibodies) and signs of severe enteropathy by duodenal biopsy examination classified as type 3 
according to Marsh classification of CD. [11] Treated CD patients were on a gluten-free diet for 
at least 2 years, showed negative coeliac serology markers and normal mucosa or infiltrative 
lesion classified as type 0-1 according to Marsh classification. 
 
Faecal microbiota composition in CD patients and control children 
The prevalence and bacterial counts of faecal samples from the three groups of children under 
study assessed by qPCR is shown in Tables 3 and 4. The prevalence of E. coli was significantly 
higher in untreated (p=0.012) and treated CD patients (p=0.031) than in control children (Table 
3). Staphylococcus was less prevalent in controls than in untreated CD patients (p=0.026) and 
treated CD patients (p=0.085).  
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Total bacterial counts were significantly lower in control children than in untreated CD (p= 
0.009) and treated CD patients (p= 0.039) (Table 4). Bacteroides and C. leptum groups were also 
present in significantly higher numbers in both untreated (p= 0.028; and 0.012, respectively) and 
treated CD patients (p= 0.015, and <0.001, respectively) compared to controls (Table 4). E. coli 
counts were also higher in both untreated and treated CD patients than in controls although the 
differences were only significant between untreated CD patients and controls (p= 0.011).Total 
bacteria, Bacteroides, C. leptum and E. coli group counts were not significant different between 
untreated and treated CD patients (p>0.05). Staphylococcus levels were significantly higher in 
untreated CD patients than in treated CD patients (p= 0.007) and controls (p= 0.031). 
Bifidobacterium counts were significantly higher in control children than in untreated (p= 0.014) 
and treated CD patients (p = 0.002). Lactobacillus group levels were significantly different only 
between treated CD patients and controls (p= 0.035).  
 
 
Duodenal microbiota composition in CD patients and control children 
The prevalence and bacterial counts of duodenal biopsies and faeces from the three studied 
groups of children (untreated and treated CD patients and controls) is shown in Table 3 and 4. 
The prevalence of C. coccoides group was higher in healthy controls than in untreated (p=0.038) 
and treated CD patients (p=0.154). Lactobacillus prevalence was significantly higher in untreated 
than treated CD patients (p=0.002) and it was also higher in controls than in treated CD patients 
(p=0.038). A. muciniphila prevalence was significantly higher (p=0.011) in untreated than in 
treated CD patients.  
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Untreated CD patients showed the highest total bacterial counts in biopsies, followed by treated 
CD patients and controls, although the differences were not significant (Table 4). Bacteroides and 
C. leptum groups were present in significantly higher numbers in both untreated (p= 0.002 and p= 
0.040, respectively) and treated (p= 0.030 and p= 0.003, respectively) CD patients than in 
controls. Staphylococcus and E. coli group were present in higher levels in untreated CD patients 
than in treated patients (p= 0.025 and 0.030, respectively) and controls (p= 0.038 and 0.030, 
respectively), whereas significant differences were not found between treated CD samples and 
control samples. Bifidobacterium counts were significantly higher in control children than in 
untreated CD patients (p = 0.009) although no differences were found comparing controls with 
treated CD patients (p = 0.461). Lactobacillus group levels were lower in treated CD patients (p < 
0.001) and controls (p< 0.001) than in untreated CD patients, whereas no differences were 
detected between controls and treated CD patients (p = 0.214).  
 
Relations between microbiota composition of biopsy and faecal samples 
The correlations found between bacterial counts of faeces and biopsies considering all samples 
are shown in Fig 1. In addition, correlations were detected between the faecal and biopsy levels 
of Bifidobacterium in untreated CD patients (R= 0.86, p< 0.001), treated CD patients (R= 0.67, 
p< 0.001) and controls (R= 0.68, p< 0.001). Correlations were also detected between the faecal 
and biopsy levels of Bacteroides (R= 0.86, p < 0.001), Staphylococcus (R= 0.80, p< 0.001), C. 
coccoides (R= 0.83, p < 0.001), C. leptum (R= 0.77, p < 0.001), Lactobacillus (R= 0.83, p < 
0.001), E. coli (R= 0.82, p <0.001) and A. muciniphila (R= 0.78, p < 0.001) in untreated CD 
patients. Similarly, correlations were detected for Bacteroides (R= 0.71 and R=0.68, p <0.001), 
Staphylococcus (R= 0.61, p =0.004 and R=0.44, p = 0.017), C. coccoides (R= 0.71 and R=0.68, p 
< 0.001), C. leptum (R= 0.67 and R=0.85, p= 0.001), Lactobacillus (R= 0.67, p = 0.001  and 
R=0.69 , p< 0.001, respectively), E. coli (R= 0.86, p= 0.05  and R=0.66, p= 0.020) in treated CD 
patients and controls. A. muciniphila correlation was only detected in controls (R=0.51, p-value = 
0.003). 
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DISCUSSION   
This is the first comparative study on the relations between the faecal and duodenal mucosa-
associated microbiota of CD patients, untreated and treated by a long-term GFD, providing new 
insights into the possible role of bacteria in CD pathogenesis at different stages of the disease.   
Bacteroides and C. leptum groups were significantly more abundant in faeces and biopsies of 
both CD patients than in healthy controls, regardless the stage of the disease. Significantly 
increased levels of Bacteroides were also previously detected in faeces and biopsies of untreated 
CD patients compared to controls by in situ hybridization and flow cytometry techniques; [3, 4] 
moreover, significant differences have been found between treated and healthy controls in both 
faeces and biopsies in the present study, providing sounder links between Bacteroides and the 
disease. With a few exceptions, [10] increased levels of Bacteroides have also been detected in 
the gut microbiota of patients suffering from Crohn’s disease, which is also characterized by Th1-
type polarized response. [12] In IBD patients the concentration of Bacteroides associated with the 
mucosa was shown to be higher and increased with the severity of the disease. [13] The obtained 
results are also in agreement with the microbial differences found between faecal samples from 
two population groups with high and low incidence of allergies and CD (Swedish and Estonian 
infants), characterized by increased levels of Bacteroides and Clostridium in the former 
population group. [14] C. leptum group has also been identified as the clostridia probably 
contributing to increases in total Clostridium levels previously detected in faeces of untreated CD 
patients compared with controls. [3] Information of the significance of this bacterial group in 
duodenal microbiota of CD patients has been newly reported here. 
The prevalence of E. coli and Staphylococcus was significantly or almost significantly higher in 
faeces of both CD patients than in those of controls. In addition, E. coli and Staphylococcus 
counts were significantly higher in faeces and biopsies of non-treated CD patients than in those of 
controls but their levels were normalized after the treatment with a GFD in parallel to the 
remission of the mucosal lesion. Therefore, these two bacterial groups seemed to be associated 
with the active phase of the disease and their increases could be a secondary consequence of the 
inflammatory milieu trigger by gluten ingestion. In IBD patients numbers of E. coli associated 
with the mucosa were also increased. [15] In addition, an adherent invasive E. coli pathovar was 
identified in the mucosa of patients with Crohn’s disease, which was able to replicate and induce 
tumour necrosis factor alpha (TNF-α) production in macrophages. [16] Increased levels of 
Staphylococcus in duodenal biopsies of untreated CD patients compared with controls have been 
detected in agreement with a previous study of faeces collected only from untreated CD patients 
[3]  
Increased levels of Staphylococcus and Enterobacteriaceae were also higher in allergy infants 
compared to healthy infants, suggesting a relationship between these bacterial groups and 
immune dysregulation. [17]  
Bifidobacterium levels were significantly lower in faeces of both CD patients as well as in 
biopsies of untreated CD patients compared to control children. A similar trend was detected in 
biopsy and faecal sample of untreated CD patients and controls but the differences were not 
significant. [3, 4] These results suggest that either Bifidobacterium could protect against CD or 
inherent features of the CD intestine influence Bifidobacterium colonization. Bifidobacterium 
numbers in the mucosa of IBD patients were also reduced compared to controls. [18, 19] The 
same trend was reported for allergic infants compared to healthy infants, [17] constituting the 
basis for the proposed use of probiotic bacteria in the management of this disorder. [20]  
Significant correlations were found between the main bacterial group counts detected in biopsies 
and faeces. In fact, similar bacterial groups were related to CD in biopsies and faeces, indicating 
that faecal microbiota partly reflects that of the small intestinal mucosa in CD patients, and could 
constitute a convenient biological marker of this disorder.  
In summary, this study has demonstrated that both duodenal and faecal microbiota is unbalanced 
in untreated CD children and only partially restored after long-term adherence to a GFD. 
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Therefore, specific components of the gut microbiota could be viewed as novel factors 
contributing to the disease and as possible faecal indexes of this disorder.  
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FIGURE LEGEND 
 
Figure 1. Correlations between bacterial group counts of faeces and duodenal biopsies from 
untreated patients (dark grey box), non-treated patients (grey box) and controls (white box). Data 
represent the positive samples. The line in the box is the median (50% percentile), with the lower 
line the lower 25% border (25% percentile) and the upper line the 75% (75% percentile) border. 
The end of the upper vertical line is the maximum data value, outliers not considered. The end of 
the lower vertical line is the lowest value, outliers not considered. The separate dots or asterisks 
indicate outliers. Correlations values included in the figure were done using all positive simples 
from faeces and duodenal biopsies. Significant correlations were established at p < 0.05. 
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